Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Eli Lilly Has More Than an Ozempic Competitor -- Much More

TheMotleyFool

0 0

Eli Lilly Has More Than an Ozempic Competitor -- Much More: https://g.foolcdn.com/editorial/images/765536/doctors-office-checkup-patient-hospital.jpg

Over the last year, Eli Lilly's (NYSE: LLY) stock is up nearly 120%. This monstrous move has helped propel the pharmaceutical leader to become the largest health care company in the world by market cap.

Although Lilly has a number of medications in its portfolio, perhaps its most popular at the moment is Mounjaro. Mounjaro is a glucagon-like peptide-1 (GLP-1) treatment for diabetes patients. It is also the primary competing product to the incredibly popular Ozempic, which was developed by Novo Nordisk.

Despite the rising popularity of GLP-1 treatments, Lilly has a lot more to offer. Let's take a deep dive into the company's entire business and understand what other catalysts could be at play.

Source Fool.com

Like: 0

LLY

Share